Posts Tagged ‘lawsuit’

New Jersey Is Sued Over the Forced Medication of Patients at Psychiatric Hospitals

Tuesday, August 3rd, 2010

New York Times
by Richard Perez-Pena
August 3, 2010

Patient advocates filed a federal lawsuit on Tuesday charging that New Jersey psychiatric hospitals routinely medicate patients against their will without a review by an outside arbiter, a practice that is banned in most other states.

Twenty-nine states require a judge’s ruling for involuntary medication, according to the suit, including New York, Connecticut and other large states, like California, Florida and Texas. Five other states leave the decision to an individual or panel outside the hospital. Some states also provide an advocate to represent a patient in a hearing on forced medication.

But in New Jersey, state rules allow a patient in a state hospital to appeal medication decisions only to people in the hospital. The lawsuit contends that the internal appeal process is routinely ignored and that psychiatric patients in private hospitals lack any opportunity to appeal medication regimens at all.

The suit, filed in Federal District Court in Trenton by the group Disability Rights New Jersey, seeks a court order requiring the state to provide judicial review of involuntary medication. It notes that a prison inmate has more power to contest treatment decisions than a psychiatric patient.

The drugs forced on patients include powerful medications for conditions like schizophrenia and bipolar disorder. They help many people with those diseases function better, but can have serious side effects, including diabetes, tremors, seizures, high blood pressure, obesity, sedation, aches and impaired mental function.

“As a patient in a state hospital, it’s your legal right to refuse and go through a process, but you get severely penalized if you try,” said W. Emmett Dwyer, litigation director of Disability Rights New Jersey, a federally financed organization. “They view you as noncompliant with treatment. They give you an injection instead of a pill. And they tell you if you don’t take it, you won’t get out.”

There are about 1,800 patients at any given time in New Jersey’s five state psychiatric hospitals, and 1,000 in private ones.

Michael D. Reisman, a lawyer with Kirkland & Ellis, which is helping bring the lawsuit, said recent records from one state hospital showed that fewer than 20 percent of patients contested their medication.

But the advocates and several former patients said many more objected to their prescriptions but submitted quietly, rather than risk painful injections or a longer hospital stay. Others, they said, are too medicated to object.

“When I said no, they just shot me up instead, so pretty soon I gave up,” said Alice Hsia, 34, who has been in and out of hospitals for schizophrenia. “The times I was sedated, I would sign anything they wanted.”

Mr. Reisman said the question often was not whether some medication was needed, but rather one of dosage or a desire to try a “different drug with fewer side effects.” Some hospital

psychiatrists do not take such concerns seriously, he said, but “a judicial hearing would give the patient more leverage and force the doctors to listen.”

The State Department of Human Services, which runs the hospitals, declined to comment on the suit. But among advocates for the mentally ill, there are wide-ranging opinions on involuntary treatment.

Phil Lubitz, associate director of the National Alliance on Mental Illness of New Jersey,  said he did not see forced medication as a major issue, noting that it was extremely difficult to get patients committed in New Jersey, and that most who were presented “a danger to themselves or others.”

But Robert Davison, executive director of the Mental health Association of Essex County,  called New Jersey’s policy “beneath contempt.”

Yana Paskova for The New York Times

Joseph Cichowski said he would have challenged forced medication if he had the opportunity.

Nicole Bengiveno/The New York Times

Alice Hsia said she submitted to prescriptions at hospitals quietly rather than risk painful injections.

Read the entire article here: http://www.nytimes.com/2010/08/04/health/policy/04psych.html

« Return to news items


  • Share/Bookmark

Glaxo To Pay $1Billion To Settle Paxil Birth Defect Cases

Wednesday, July 21st, 2010

Pharmalot
By Ed Silverman
July 21, 2010

In an effort to get its arms around massive litigation, GlaxoSmithKline has agreed to settle yet another wad of product-liability lawsuits involving one of its popular meds. The latest deal involves an agreement to pay more than $1 billion to settle some 800 cases alleging its Paxil antidepressant caused birth defects in children borne to women who took the drug, Bloomberg News writes.

The move comes after a Pennsylvania state court jury last October awarded a woman $2.5 million in damages for failing to properly warn docs and pregnant women about the risks of the antidepressant. This case, which was filed by the family of a three-year-old boy who was born with heart defects his mother blamed on the drug. It was the first of 600 such lawsuits and was seen as a test of Glaxo’s vulnerability (background).

Last week, Glaxo disclosed plans to take a $2.4 billion charge in its second quarter to settle product-liability lawsuits over its Avandia diabetes pill, litigation involving the Paxil antidepressant and a US government investigation into its manufacturing site at Cidra, Puerto Rico.

The Paxil deal, which would provide an average payout of more than $1.2 million to families of the affected children, leaves more than 100 similar cases pending. The birth-defect settlements bring to more than $2 billion the amount Glaxo has agreed to pay to resolve a variety of Paxil-related suits, including claims the pill caused suicides or attempted suicides and addiction problems, Bloomberg writes.

Read the entire article here:  http://www.pharmalot.com/2010/07/glaxo-to-pay-1b-to-settle-paxil-birth-defect-cases/

See all international studies/warnings on Paxil: http://www.cchrint.org/psychdrugdangers/drug_warnings.php

See what doctors, pharmacists, health care providers and others have reported to the US FDA on Paxil side effects (such as birth defects): http://www.cchrint.org/psychdrugdangers/medwatch_psych_drug_adverse_reactions.php

« Return to news items


  • Share/Bookmark

GlaxoSmithKline settles case with woman who linked her use of antidepressant Paxil to the death of her infant son

Monday, July 19th, 2010

The Associated Press
By Wayne Ortman
July 19, 2010

SIOUX FALLS, S.D. — A settlement has been reached in a lawsuit filed against a pharmaceutical company by a Watertown woman who linked her prescribed use of Paxil to the death of her infant son, according to court files.

Jennifer Berg of Watertown sued SmithKline Beecham, doing business as GlaxoSmithKline, in October 2007. The complaint said Nathan Berg died in 2004 because of a heart disorder caused by her use of the antidepressant Paxil while she was pregnant.

The federal court lawsuit sought unspecified damages from the company for failing to warn of a link between the two. Letters from her attorneys to the presiding judge indicate there’s a settlement. No settlement documents have been filed in court.

Lawyers at a California firm handling the case for Berg did not immediately return a phone call Monday for comment.

GlaxoSmithKline said last week that it expects to take a $2.36 billion charge against second-quarter earnings for settlements, agreements to settle and other provisions for long-standing legal cases over Paxil, the diabetes drug Avandia and other issues. The company said settlement details would be confidential.

According to the lawsuit, Nathan Berg was born Aug. 20, 2004 at Watertown and was immediately transferred to a Minneapolis hospital where he died 58 days later of Persistent Pulmonary Hypertension of the Newborn (PPHN), a disorder which prevents proper oxygenation of the blood.

“At the time Paxil was prescribed to Ms. Berg, GSK (GlaxoSmithKline) knew or should have known through pre-market studies and post-market studies and reports that Paxil was associated with an increased risk of PPHN in babies whose mothers ingested Paxil during pregnancy,” according to the lawsuit.

Read entire article:  http://www.google.com/hostednews/ap/article/ALeqM5j7UU4otrHhelqaJFcC3ttvwj4bYgD9H29RK00

« Return to news items


  • Share/Bookmark

AstraZeneca Denied Antipsychotic Drug’s Link to Diabetes for Years After Admitting Link to Japanese Physicians

Thursday, June 17th, 2010

Natural News
By David Gutierrez
June 17, 2010

Drug giant AstraZeneca attempted to obscure the connection between one of its blockbuster drugs and diabetes risk for years after it knew of the problem, according to documents recently unsealed as part of lawsuits against the company.

More than 15,000 patients have sought damages from the company, alleging that they were harmed by side effects from its atypical antipsychotic Seroquel. According to the plaintiffs, AstraZeneca deliberately hid information linking the drug to an increased risk of weight gain and diabetes. The lawsuits have been consolidated into a single case for the purpose of pre-trial proceedings.

The recently unsealed documents include notes from a meeting between salesperson Nancy White and a doctor in July 2006, during which the doctor said that his patients were expressing concern about Seroquel’s links to diabetes. White reported telling the doctor that “there has been no causative effect” proven between the drug and the disease.

Yet in November 2002, AstraZeneca had issued a warning to doctors in Japan that due to dozens of reports linking Seroquel to diabetes, “causality with the drug could not be ruled out.” The company cautioned doctors not to prescribe the drugs to diabetics and to encourage all Seroquel patients to monitor their blood sugar. Just over a year later, the company issued a similar warning to doctors in the United States.

Read entire article:  http://www.naturalnews.com/029012_AstraZeneca_diabetes_drug.html

« Return to news items


  • Share/Bookmark

Wrongful Death Suit Claims Anti-depressant Led to Elderly Couple’s Murder-Suicide

Friday, May 28th, 2010

The West Virginia Record
By Lawrence Smith
May 28, 2010

RIPLEY — The murder-suicide of a Jackson County couple is at the center of a wrongful death, and product liability suit against New York pharmaceutical company.

Forest Laboratories and Forest Pharmaceuticals are named as co-defendants in a lawsuit filed in Jackson Circuit Court on April 30 by Robin J. Hall. In her six-count complaint, Hall, 49, a resident of Staats Mill, alleges Forest failed to alert both her father, and his physician of potentially dangerous side-effects of medication he was taking which resulted in him taking the life of his wife, then his own.

Located in New York, N.Y., Forest Laboratories is the parent company of Forest Pharmaceuticals based in St. Louis, Mo. Forest Pharmaceuticals handles the manufacture, sell and distribution of all Forest products in the United States.

In her suit, Hall says her father, Robert Raines, was prescribed Celexa by his doctor on April 24, 2008. Later that day, Raines purchased Celexa in 20 mg tablets.

Celexa is the brand name for Citalopram, a psychoactive drug in the class of selective serotonin reuptake inhibitors. It is used mostly for treatment of depression by altering a person’s serotonin levels.

Forest, Hall alleges, was aware Celexa caused an increased risk of suicidal behavior in people over 65, yet failed to conduct any further testing or investigation. Also, she alleges in its promotional materials, Forest failed to warn not only patients, but also physicians and pharmacists of that risk.

As early as Oct. 15, 2004, Forest was aware of the causality between SSRI drugs like Celexa and suicidal behavior in children. It was then, the U.S. Food and Drug Administration ordered Forest to put a “black box warning” on Celexa for anyone under the age of 24 about the potential risk of suicidal behavior.

Read entire:  http://www.wvrecord.com/news/227152-anti-depressant-led-to-elderly-couples-murder-suicide-jackson-suit-claims

« Return to news items


  • Share/Bookmark

Lawsuit Alleges Johnson & Johnson Pushed Drugs on Seniors

Thursday, April 8th, 2010

ConsumerAffairs.com
By Jon Hood
April 8, 2010

A lawsuit filed last week accuses Johnson & Johnson of conspiring with pharmaceutical consultant Omnicare in an effort to push J&J drugs on nursing home residents, and violating federal Medicaid laws in the process.

As a result of the scheme, “residents were overcharged for their medications, had additional medications administered and were unlawfully switched to Johnson & Johnson drugs,” all in the name of increasing revenue, according to the lawsuit.

The suit, filed in federal court in California, says Omnicare — which “occupies a ‘dual’ role of a dispensing pharmacy and consulting pharmacy” — gave certain J&J drugs “elevated status as the default drug of choice” for thousands of nursing home patients. J&J allegedly gave Omnicare “performance rebates” — essentially kickbacks — in return for its services. This arrangement was memorialized in a 1997 “Supply Agreement” between the two companies, the suit states.

The agreement provided that the two companies would “meet quarterly to review their joint ‘business plan’ and ‘performance goals,’” and came up with a novel way to deal with the performance-rebates: they would be treated as year-end bonuses.

The drugs allegedly targeted for promotion under the agreement included Floxin, Levaquin, Risperdal, Ultram, Duragesic, Procrit, and Aciphex.

The suit contends that under the agreement, J&J paid to have its drugs labeled as “preferred” — a status that Omnicare purportedly confers on drugs that receive high marks “for their clinical effectiveness in the geriatric community.”

Read entire article:  http://www.consumeraffairs.com/news04/2010/04/jnj_omnicare_suit.html

« Return to news items


  • Share/Bookmark

Risperdal (an antipsychotic) Lawsuits Filed Over Breast Growth Among Boys

Monday, January 11th, 2010

AboutLawsuits.com
January 11, 2010

At least 10 families have filed lawsuits against the makers of Risperdal and Invega, alleging that the antipsychotic medications, often used to treat attention deficit disorder and autism, caused teen boys to grow breasts measuring as large as a 38D cup size in some cases.

The lawsuits were filed recently in the Philadelphia Court of Common Pleas by the families of boys who took the medications and experienced the noticeable breast growth side effects. The Invega and Risperdal lawsuits accuse the manufacturers of negligence and fraud, and say they failed to adequately warn users about the potential male breast growth effects of the drugs when given to teen boys. Most of the lawsuits involve the use of Risperdal alone.

Risperdal (risperidone) and Invega (paliperidone) are manufactured by Janssen, a division of Ortho-McNeil-Janssen, a subsidiary of Johnson and Johnson. Risperdal is approved by FDA for the treatment of schizophrenia, bipolar disorder and autism. Invega is approved for the treatment of schizophrenia.

The complaints allege that the boys experienced dramatic breast growth that was in addition to significant weight gain side effects of Risperdal and Invega. The boys’ doctors initially missed or dismissed signs of breast growth, assuming it was connected to the increases in weight. In some cases, the boys grew breasts as large as 38D, and the complaints indicate that some of the youths will require surgery for breast removal.

Read entire article: http://www.aboutlawsuits.com/risperdal-lawsuits-over-breast-growth-boys-7598/

« Return to news items


  • Share/Bookmark

Eli Lilly’ s confidential settlement with seven states over its antipsychotic drug Zyprexa

Thursday, September 24th, 2009

Bob Van Voris, Margaret Cronin Fisk and Jef Feeley
Bloomberg.com
September 21, 2009

Eli Lilly & Co. agreed to settle, on confidential terms, lawsuits filed by seven states alleging the company improperly marketed its antipsychotic drug Zyprexa, a court-appointed official said.

“All of the states have essentially settled for the same” non-monetary arrangements, said Michael Rozen, special master appointed by the court to help settlement negotiations. The money terms, which weren’t disclosed, “have fallen roughly in line,” he said at a hearing today in federal court in Brooklyn, New York.

Lawyers told U.S. District Judge Jack B. Weinstein, who is overseeing the cases, that finishing the settlements may be delayed while the parties determine how much money the U.S. government plans to claim in compensation for federal dollars spent on Zyprexa through state Medicaid programs.

If completed and approved in court, the settlements would leave four suits filed by states pending against Lilly.

Read entire article: http://www.bloomberg.com/apps/news?pid=20601103&sid=aUgLzDmvzVK0

« Return to news items


  • Share/Bookmark

On trial – Did drug giant GlaxoSmithKline know Paxil could cause birth defects more than 20 years ago?

Wednesday, September 16th, 2009

Jef Feeley and Margaret Cronin Fisk
Bloomberg.com
September 16, 2009

Sept. 15 (Bloomberg) — An executive of GlaxoSmithKline, the world’s second-biggest drugmaker, talked about burying negative studies linking its antidepressant drug Paxil to birth defects, according to a company memo introduced at a trial.

“If neg, results can bury,” Glaxo executive Bonnie Rossello wrote in a 1997 memo on what the company would do if forced to conduct animal studies on the drug. The memo was read during opening statements in the trial of a lawsuit brought by the family of a child born with heart defects.

The Philadelphia trial is the first of more than 600 cases alleging that London-based Glaxo knew Paxil caused birth defects and hid those risks to pump up profits. The drug, approved for U.S. use in 1992, generated about $942 million in sales last year, 2.1 percent of Glaxo’s total revenue.

The family of Lyam Kilker claims Glaxo withheld information from consumers and regulators about the risk of birth defects and failed to properly test Paxil. Kilker’s mother, Michelle David, blames Paxil for causing life-threatening heart defects in her 3-year-old son.

Read entire article: http://www.bloomberg.com/apps/news?pid=20601087&sid=ah9mMl9sDitg

« Return to news items


  • Share/Bookmark